Aptevo (APVO) CEO Jeffrey Lamothe Receives 961 Shares from RSU Vest

What Happened

• Jeffrey G. Lamothe, President, CEO and Director of Aptevo Therapeutics (APVO), had 961 restricted stock units (RSUs) convert into 961 common shares on August 6, 2026 (reported as exercise/conversion, code M). The filing also reports a disposition of 961 shares on the same date at $0.00 (derivative). No cash proceeds are reported. This is a vesting/conversion event rather than an open-market purchase or sale.

Key Details

• Transaction date(s): August 6, 2026
• Acquisition: 961 shares via exercise/conversion (code M) — price listed as N/A
• Disposition: 961 shares at $0.00 (derivative)
• Footnotes: F1 — RSUs convert one-for-one into common stock; F2 — these RSUs were granted Aug 6, 2025 (17,300 originally; 961 post-split) and vested on the first anniversary
• Shares owned after transaction: not specified in the provided excerpt
• Filing: Form 4 filed Aug 10, 2026 for an Aug 6 transaction — appears later than the typical 2-business-day Form 4 deadline (may be marked late)

Context

• RSUs convert into shares on vesting; companies commonly withhold or retire shares to satisfy tax obligations or settle awards. The filing shows a conversion of 961 RSUs and an immediate disposition of 961 shares at $0.00, which indicates no cash sale was reported. This looks like a routine RSU vesting/net settlement event, not an open-market buy or sale; retail investors should not infer insider buying or selling intent from this filing alone.